283 related articles for article (PubMed ID: 7476909)
41. Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity.
Constantinou A; Henning-Chubb C; Huberman E
Cancer Res; 1989 Mar; 49(5):1110-7. PubMed ID: 2537141
[TBL] [Abstract][Full Text] [Related]
42. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
Qiu J; Catapano CV; Fernandes DJ
Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
[TBL] [Abstract][Full Text] [Related]
43. [Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase II inhibitors adriamycin and etoposide].
Meliksetian MB; Berezkina EV; Pavlenko MA; Grinchuk TM
Tsitologiia; 1999; 41(7):615-21. PubMed ID: 10496023
[TBL] [Abstract][Full Text] [Related]
44. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
45. Reduced topoisomerase II-mediated DNA cleavage in VP-16 resistant human leukemic cell line.
Saijo Y; Satoh K; Tokue Y; Kumano N; Motomiya M
Anticancer Res; 1991; 11(1):445-8. PubMed ID: 1850222
[TBL] [Abstract][Full Text] [Related]
46. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
47. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
48. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
[TBL] [Abstract][Full Text] [Related]
49. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
50. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
51. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
52. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
53. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
54. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells.
Kataoka S; Naito M; Tomida A; Tsuruo T
Exp Cell Res; 1994 Nov; 215(1):199-205. PubMed ID: 7957669
[TBL] [Abstract][Full Text] [Related]
55. Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SY5Y human neuroblastoma cells through an alpha-, beta-, and zeta-protein kinase C-independent pathway.
Jalava A; Akerman K; Heikkilä J
J Cell Physiol; 1993 May; 155(2):301-12. PubMed ID: 8482723
[TBL] [Abstract][Full Text] [Related]
56. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Zwelling LA; Hinds M; Chan D; Altschuler E; Mayes J; Zipf TF
Cancer Res; 1990 Nov; 50(22):7116-22. PubMed ID: 2171756
[TBL] [Abstract][Full Text] [Related]
57. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
58. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
59. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
Anyanwutaku IO; Guo X; Chen HX; Ji Z; Lee KH; Cheng YC
Mol Pharmacol; 1996 Apr; 49(4):721-6. PubMed ID: 8609902
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
